4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)-oxy)-6-(cyclopropyl(methyl)amino)-1-methylpyrimidin-2(1H)-one

ID: ALA3794025

Chembl Id: CHEMBL3794025

PubChem CID: 121448402

Max Phase: Preclinical

Molecular Formula: C23H19ClF5N3O3

Molecular Weight: 515.87

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN(c1cc(OCc2cc(F)c(Oc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)nc(=O)n1C)C1CC1

Standard InChI:  InChI=1S/C23H19ClF5N3O3/c1-31(13-3-4-13)20-10-19(30-22(33)32(20)2)34-11-12-7-17(25)21(18(26)8-12)35-14-5-6-16(24)15(9-14)23(27,28)29/h5-10,13H,3-4,11H2,1-2H3

Standard InChI Key:  XBEMBJJFOOIYGP-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3794025

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 515.87Molecular Weight (Monoisotopic): 515.1035AlogP: 5.70#Rotatable Bonds: 7
Polar Surface Area: 56.59Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 0.99CX LogP: 5.62CX LogD: 5.62
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.38Np Likeness Score: -1.23

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source